IDH1 and lung adenocarcinoma: We obtained detailed treatment and survival data of 8 patients with active‐site IDH1/2 mutations and found that seven of them (87.5%) showed high‐grade features (stage IV), whereas the other patients exhibited resectable stage III lung adenocarcinoma.